I agree, BUT I do believe there are plenty of catalysts on the horizon. You know how this goes. Every early biotech C is volatile but usually declines. In this case, it has 4 compounds that all show positive data comparable to what's out there with minimal side effects. One deal or collaboration with a big Pharma and this thing could explode. That's what people are waiting for. I think this will bottom out at .38 or so and I will buy more. If this thing doubles in the next year its well worth it for me.
I disagree again that there are no catalysts for it. Cancer is like terrorism, you have to attack it on multiple fronts and reduce it as much as possible. There is always room for one more compound especially again with minimal side effects. Could you imagine 10 years down the line when this thing has one of those drug commercials and it states it has 1% the side effects of chemo for instance? I feel better about this one than many others I'm holding.